权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

CANCER PHARMACOLOGY CORE

癌症药理学核心

基本信息

批准号：
7529385
负责人：
Charles Leslie Hoppel
金额：
$ 8.75万
依托单位：
CASE WESTERN RESERVE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-07-06 至 2012-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7529385
关键词：
Antineoplastic Agents Atmospheric Pressure Behavior Biological Assay Cancer Center Cancer Therapy Evaluation Program Categories Clinical Research Clinical Trials Core Facility Databases Development Developmental Therapeutics Program Drug Design Drug Formulations Drug Kinetics Elements Funding Grant Laboratories Letters Methodology Methods Mission Molecular Weight O(6)-benzylguanine Operative Surgical Procedures Optics Pharmaceutical Preparations Pharmacology Phase Rebeccamycin Analogue Recommendation Research Design Research Personnel Sampling Schedule Thalidomide Therapeutic Therapeutic Agents Translational Research United States National Institutes of Health Work analytical method base cancer pharmacology cancer therapy chemotherapeutic agent concept design detector docetaxel dosage instrument ionization mass spectrometer method development methoxyamine novel phthalocyanine Pc 4 programs sample collection silicon phthalocyanine small molecule symposium

项目摘要

The Cancer Pharmacology Core Facility (CPCF) provides an analytical laboratory for accurate and sensitive chromatographic determination of chemotherapeutic drugs and some drug metabolites. The facility staff provides the expertise necessary for development of thoroughly validated drug determination methods. The staff also participates in the design of clinical studies of chemotherapeutic agents by specification of sample collection methodology and recommendation of sampling intervals on the basis of expected pharmacokinetic behavior of studied therapeutic agents. The facility determines drugs in dosage formulations as an element of study design in most of the clinical trials in which we participate. The CPCF has an atmospheric pressure ionization triple quadrupole mass spectrometer (API/MS) which was purchased with NIH BRS shared instrument program grant funds. This instrument is very selective and sensitive toward certain categories of small molecules which include many cancer treatment drugs of low molecular weight. This instrument enables us to bring analytical methods into operation sooner than is possible with optical chromatographic detectors. The availability of this instrument within the CPCF has enabled the Cancer Center to attract funding for clinical trials of thalidomide in combination with docetaxel, and OSI-774 in combination with docetaxel. The facility maintains a database of these analytical results, and it conducts pharmacokinetics analysis of those results.

癌症药理学核心设施（CPCF）提供了一个分析实验室，色谱法测定化疗药物和某些药物代谢物。设施工作人员为开发经过充分验证的药物测定方法提供必要的专业知识。的工作人员还参与化学治疗药物临床研究的设计，基于预期药代动力学的采集方法和采样间隔建议研究的治疗药物的行为。该设施确定药物的剂量配方作为一个元素在我们参与的大多数临床试验中， CPCF具有大气压电离三重四极杆质谱仪（API/MS），使用NIH BRS共享仪器计划赠款资金购买。该仪器选择性很强，对某些类别的小分子敏感，包括许多低分子量的癌症治疗药物。分子量的这台仪器使我们能够比以前更快地采用分析方法。光学色谱检测器。该工具在CPCF中的可用性使癌症中心能够吸引资金用于沙利度胺联合多西他赛的临床试验，和OSI-774与多西他赛的组合。该设施维护这些分析结果的数据库，它对这些结果进行药代动力学分析。